Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa - Scorecard - MDSpire
Advertisement
Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa
Clinical Scorecard: Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa
At a Glance
Category
Detail
Condition
Drug-Resistant Tuberculosis (DR-TB)
Key Mechanisms
Rapid molecular testing and phenotypic drug susceptibility testing (DST) for effective diagnosis and management.
Target Population
Patients with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in South Africa.
Care Setting
Healthcare providers in South Africa.
Key Highlights
In 2023, only 40% of global MDR/RR-TB cases were diagnosed and treated.
South Africa reported 13,000 MDR/RR-TB cases, with a high mortality rate of 21%.
Rapid molecular tests significantly improve the speed of DR-TB diagnosis.
Only 47% of newly diagnosed TB cases in South Africa received rapid molecular testing.
The cost-effectiveness of combining rapid molecular assays with pDST remains underexplored.
Guideline-Based Recommendations
Diagnosis
Universal access to drug susceptibility testing (DST) is recommended by WHO.
Rapid testing for resistance to rifampicin (RIF), isoniazid (INH), and fluoroquinolones (FQs) is essential.
Management
Treatment regimens should align with South African and WHO guidelines for DR-TB.
Monitoring & Follow-up
Monitor treatment success rates and adjust based on pDST results.
Risks
Delayed diagnosis can lead to inappropriate treatment and increased mortality risk.
Patient & Prescribing Data
Microbiologically confirmed TB patients in South Africa.
Early treatment initiation is crucial for improving outcomes in DR-TB patients.
Clinical Best Practices
Implement rapid molecular diagnostics to enhance early detection of DR-TB.
Utilize combination strategies of rapid molecular tests and pDST for accurate diagnosis.
Ensure adherence to WHO recommendations for drug susceptibility testing.
Amoxicillin-clavulanate was not linked to lower treatment failure but was associated with a slightly higher risk of secondary infections compared with amoxicillin in adults with uncomplicated acute sinusitis.
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
